COX-2 inhibitors and cardiovascular risk - The data are inconclusive, and these drugs are needed

被引：4
|
作者：
Lipani, J [1 ]
机构：
[1] Histatek Inc, Fountain Hills, AZ USA
来源：
CLEVELAND CLINIC JOURNAL OF MEDICINE | 2001年 / 68卷 / 11期
关键词：
D O I：
10.3949/ccjm.68.11.961
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
下载
收藏
页码：961 / 962
页数：2
相关论文
共 50 条
  • [1] COX-2 inhibitors and cardiovascular risk
    Funk, Colin D.
    FitzGerald, Garret A.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2007, 50 (05) : 470 - 479
  • [2] COX-2 Inhibitors and Cardiovascular Risk
    Cannon, Christopher P.
    Cannon, Paul J.
    SCIENCE, 2012, 336 (6087) : 1386 - 1387
  • [3] Cox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitors
    Debabrata Mukherjee
    Eric J Topol
    Arthritis Res Ther, 5
  • [4] COX-2 inhibitors: cancer prevention or cardiovascular risk?
    Senior, K
    LANCET ONCOLOGY, 2005, 6 (02): : 68 - 68
  • [5] Risk of cardiovascular events associated with COX-2 inhibitors
    不详
    HOSPITAL MEDICINE, 2001, 62 (09): : 577 - 577
  • [6] COX-2 inhibitors and cardiovascular risk - Point and counterpoint
    Mandell, BF
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2001, 68 (11) : 957 - 960
  • [7] Cardiovascular Risk Associated With NSAIDs and COX-2 Inhibitors
    Perry, Laura A.
    Mosier, Charles
    Atkins, Ashton
    Minehart, Megan
    US PHARMACIST, 2014, 39 (03) : 35 - 38
  • [8] Are COX-2 inhibitors a risk factor for cardiovascular disease?
    John, S
    Schmieder, RE
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2002, 127 (04) : 156 - 159
  • [9] Rofecoxib, selective COX-2 inhibitors and cardiovascular risk
    Dhaun, N.
    Maxwell, S. R. J.
    Webb, D. J.
    JOURNAL OF THE ROYAL COLLEGE OF PHYSICIANS OF EDINBURGH, 2005, 35 (02): : 101 - 103
  • [10] COX-2 inhibitors and cardiovascular risk - We defend our data and suggest caution
    Mukherjee, D
    Nissen, SE
    Topol, EJ
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2001, 68 (11) : 963 - 964
12345